An update on the diagnosis and treatment of sinusitis and nasal polyposis

Bachert, Claus; Hörmann, K.; Mösges, Ralph; Rasp, Gerd; Riechelmann, Herbert; Müller, Rainer; Luckhaupt, H.; Stuck, BA; Rudack, Claudia

doi:10.1034/j.1398-9995.2003.02172.x

Cited by 149 publications

(148 citation statements)

References 162 publications

(150 reference statements)

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…By contrast, no evidence has been seen so far that indicates that pDC play a role in lower respiratory tract immunology (40). A number of mechanisms described above could account for the effects of therapeutic treatment strategies such as the use of topical corticosteroids in suppressing the seasonal increases in the number of nasal mucosal CD1 + LC by the inhibition of the release of cytokines such as Granulocyte-Macrophage-Colony-StimulatingFactor (GM-CSF) from the epithelial cells of the respiratory tract and IL-4, which favour the activation and differentiation of DC in vivo and in vitro (39,(41)(42)(43)(44)(45).…”

Section: Antigen Presenting Cells Of the Nasal Mucosamentioning

confidence: 99%

The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies

Novak

Allam

Betten

et al. 2003

Allergy

View full text Add to dashboard Cite

It has been repeatedly demonstrated that allergic reactions are driven by the continuous flow of antigen uptake and presentation processes, which are perpetuated mainly by dendritic cells (DC). The ability of allergens to cause allergic inflammation is contingent upon the presence of an immunological milieu and microenvironment that either privileges Th2 responses or prohibits these reactions by the induction of contraregulatory anti‐inflammatory activities of the immune system. In the light of recent developments it appears that DC have to manage two opposing tasks: on the one hand they can favor pro‐inflammatory reactions and actively induce a T‐cell response, yet on the other hand they serve an important function as ‘silencers’ in the immune system by sending out anti‐inflammatory, tolerance inducing signals. This unique capacity of DC has opened several exciting possibilities for a role of DC in both – accelerating and slowing down allergic reactions. It is therefore a challenge to understand in which way DC subtypes located at distinct anatomic sites with frequent allergen exposure, such as the skin, the nasal mucosa, the respiratory tree or the mucosa of the intestinal tract can have an impact on mechanisms involved in tolerance induction or effective immunity.

show abstract

Section: Antigen Presenting Cells Of the Nasal Mucosamentioning

confidence: 99%

The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies

Novak

Allam

Betten

et al. 2003

Allergy

View full text Add to dashboard Cite

show abstract

“…2,[91][92][93] Nasal polyps are growths that develop in the nasal and sinus membranes and extend into the nasal cavity, causing obstruction and interference with breathing. Nasal polyposis also impairs sense of smell 2,94 and has been found to impact negatively on QOL and sleep. 95 Intranasal corticosteroids are effective in treating nasal polyposis, possibly by downregulating the expression and production of cytokines such as IL-5, which effectively reduces the number of eosinophils.…”

Section: Acute Rhinosinusitis and Nasal Polyposis: Association With Amentioning

confidence: 99%

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Storms¹

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems.In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators -and therefore nasal congestion and other symptoms -should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.

show abstract

“…Слизистая оболочка носа и ОНП представляет собой еди-ный континуум, в связи с чем у подавляющего большин-ства пациентов с симптомами РС также присутствует ри-нит [5,[11][12][13][14][15], а у 90% пациентов с заложенностью носа вследствие неосложненной простуды, по данным ком-пьютерной томографии, выявляется патология синусов [16].…”

Section: этиология и патогенезunclassified